| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
DMK Pharmaceuticals Corporation (NASDAQ:DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, today announced the presentation of preclinical results comparing the effects of DPI-125 on opioid withdrawal behaviors to methadone and buprenorphine, the standard of care for opioid use disorder (OUD), in a poster session at the Society for Neuroscience Annual Meeting (SfN Neuroscience 2023) held November 11-13, 2023 in Washington D.C. DPI-125 is a novel, small-molecule triple (mu, delta and kappa) opioid receptor agonist, being developed for the treatment of opioid use disorder.
"Only about 12% of patients receive treatment for OUD, despite the proven efficacy of current medications. Buprenorphine, the market leader with US sales in excess of $3B in 2022, requires an induction phase to induce withdrawal symptoms prior to initiating the first dose. It is challenging for a patient to voluntarily experience these symptoms. In addition, buprenorphine can be abused. For this and other reasons, widespread adoption is low. We believe that DPI-125, our novel clinical stage compound, will be able to overcome this and several other barriers to treatment initiation and maintenance. The positive data to be presented today marks the first step to realizing this promise," said Eboo Versi, M.D., Ph.D., CEO of DMK Pharmaceuticals. "We are excited to present preclinical data comparing DPI-125, a triple opioid agonist, to the standard of care treatments buprenorphine and methadone to alleviate withdrawal symptoms. This preclinical study was financially supported by a grant from the National Institute of Drug Abuse (NIDA), and we believe that it warrants further development."
Details of the poster are as follows:
Title: Effect of DPI-125 on opioid withdrawal behaviors in rats: a comparison study with
methadone and buprenorphine
Program Number / Poster Number: Poster 297.01 / SS14
Session Title: G.09. Drugs of Abuse and Addiction
Session Date, Time: Monday, November 13, 2023, 1:00 p.m. - 5:00 p.m. ET
Presenter: Adam Mar, Ph.D., Assistant Professor, Department of Neuroscience and Physiology at NYU Grossman School of Medicine
Location: WCC Halls A-C
The poster will be available on DMK's website following the presentation session.
For more details about the Society for Neuroscience Annual Meeting, please visit: https://www.sfn.org/meetings/neuroscience-2023
Posted In: DMK
